Clerio Vision
Clerio Vision is a development-stage ophthalmic medical device company based in Rochester, New York, commercializing LIRIC (Laser Induced Refractive Index Change) — a non-invasive femtosecond-laser platform, licensed from the University of Rochester's Center for Visual Science, that alters the refractive index of corneal tissue and of polymer optics without cutting or removing material. The company applies LIRIC across four ophthalmic segments: multifocal soft contact lenses for presbyopia, myopia control in children, post-implant intraocular lens (IOL) optimization after cataract surgery, and incisionless corneal refractive correction. Clerio has raised roughly $40 million from Safar Partners, Armory Square Ventures, Topmark Partners, Proxima Ventures, Atma Capital, Hegemon Capital and the National Science Foundation, and holds more than 90 patents across over 30 families. Its products are lasers, optics and lenses rather than software; the company publishes a single-page marketing and investor website and operates no public developer program, API, SDK or developer portal.
Clerio Vision is profiled on the APIs.io network. Tagged areas include Company, Medical Devices, Ophthalmology, Vision Care, and Health.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Access & Security 1
Authentication, authorization, and security posture
Company 2
The organization behind the API